Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
The Global Cancer Gene Therapy Market is anticipated to witness impressive growth during the forecast period. Growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increases the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on cancer treatment across the globe, is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.
Increasing research and development activities
Increasing research and development activities and technological advancement with developed healthcare infrastructure is the major factor for the growth of the cancer gene therapy market during the forecast period. Government organizations are focusing on developed infrastructure with higher profit. Different type of innovative therapies is available for cancer therapy which is ethically acceptable, and the increasing development of new products are expected to boost the market growth over the years. The growing regulatory environment has enhanced the demand for cancer gene therapy which will boost market growth during the forecast period. Due to their direct connection to consumer health, regulations are placed on producers to assure the release of products that are free from flaws which can drive market growth over the years. Some laws have been changed to prevent product recalls during post-marketing surveillance since any flaws in gene therapy goods could be disastrous for patients. However, the expansion of the cancer gene therapy market in the years to come will be aided by the growing availability of high-quality cancer gene therapy. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer.
Growing advancement in gene therapy
The increasing prevalence rate of lifestyle disorders such as diabetes and obesity, excessive alcohol consumption, tobacco use, low physical activity, high body mass index, and low intake of fruits and vegetables because of the growing population is further expected to create a lucrative growth of the market during the forecast period. In march 2022, the National Heart, Lung, and Blood Institute granted USD 12 million to an Indiana University School of Medicine Researcher. This grant is for developing a major part of a gene therapy approach to safer and potentially curative treatments for hemophilia diseases. So different private and government organizations are investing in gene therapy for curing cancer diseases across the globe. Similarly, increasing demand for laboratory automation and growing awareness of preventative healthcare are the major factors that will boost the market growth over the years. The rise in cancer cases is primarily affecting the growth of the industry, being the second largest death cause in the world. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States, and 606,520 people will die from the disease.
Market Segmentation
The Global Cancer Gene Therapy Market can be segmented by therapy, indication, end user, and by region. Based on therapy, the market can be segmented into Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others. Based on indication, the market can be segmented into Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others. Based on the end user, the market can be differentiated by Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. Amongst the different countries, the United States dominates the global cancer gene therapy market on account of the growing demand for advanced therapy with low costs for curing cancer diseases in the country.
Recent Development
- In Sept 2021, Adaptimmune collaborated with Genentech to develop allogeneic cell therapies indicated for the treatment of multiple cancers.
- In June 2021, Eisai and Bristol Myers Squibb agreed to partner for the development and commercialization of Eisai's ADC, MORAb-202, for the treatment of advanced solid malignancies.
- In June 2021, GSK and iTeos Therapeutics partnered to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for the treatment of advanced solid malignancies.
Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA are some of the leading players operating in the Global Cancer Gene Therapy Market.
Report Scope:
In this report, global cancer gene therapy systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Cancer Gene Therapy Market, By Therapy:
- Oncolytic Virotherapy
- Gene Induced Immunotherapy
- Gene Transfer
- Others
- Cancer Gene Therapy Market, By Indication:
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Liver Cancer
- Pancreatic Cancer
- Prostate Cancer
- Others
- Cancer Gene Therapy Market, By End User:
- Biotechnology & Pharmaceutical Companies
- Academic & Research Institutions
- Others
- Cancer Gene Therapy Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Cancer Gene Therapy Market.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
- 2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Voice of Customer
- 5. Clinical Trial Analysis
- 5.1. Ongoing Clinical Trials
- 5.2. Completed Clinical Trials
- 5.3. Terminated Clinical Trials
- 5.4. Breakdown of Pipeline, By Development Phase
- 5.5. Breakdown of Pipeline, By Status
- 5.6. Breakdown of Pipeline, By Study Type
- 5.7. Breakdown of Pipeline, By Region
- 5.8. Clinical Trials Heat Map
- 6. Global Cancer Gene Therapy Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
- 6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
- 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
- 6.2.4. By Region
- 6.2.5. By Company (2022)
- 6.3. Market Map
- 7. North America Cancer Gene Therapy Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Therapy
- 7.2.2. By Indication
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Cancer Gene Therapy Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Therapy
- 7.3.1.2.2. By Indication
- 7.3.1.2.3. By End User
- 7.3.2. Canada Cancer Gene Therapy Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Therapy
- 7.3.2.2.2. By Indication
- 7.3.2.2.3. By End User
- 7.3.3. Mexico Cancer Gene Therapy Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Therapy
- 7.3.3.2.2. By Indication
- 7.3.3.2.3. By End User
- 8. Europe Cancer Gene Therapy Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Therapy
- 8.2.2. By Indication
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. France Cancer Gene Therapy Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Therapy
- 8.3.1.2.2. By Indication
- 8.3.1.2.3. By End User
- 8.3.2. Germany Cancer Gene Therapy Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Therapy
- 8.3.2.2.2. By Indication
- 8.3.2.2.3. By End User
- 8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Therapy
- 8.3.3.2.2. By Indication
- 8.3.3.2.3. By End User
- 8.3.4. Italy Cancer Gene Therapy Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Therapy
- 8.3.4.2.2. By Indication
- 8.3.4.2.3. By End User
- 8.3.5. Spain Cancer Gene Therapy Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Therapy
- 8.3.5.2.2. By Indication
- 8.3.5.2.3. By End User
- 9. Asia-Pacific Cancer Gene Therapy Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Therapy
- 9.2.2. By Indication
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Cancer Gene Therapy Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Therapy
- 9.3.1.2.2. By Indication
- 9.3.1.2.3. By End User
- 9.3.2. India Cancer Gene Therapy Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Therapy
- 9.3.2.2.2. By Indication
- 9.3.2.2.3. By End User
- 9.3.3. Japan Cancer Gene Therapy Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Therapy
- 9.3.3.2.2. By Indication
- 9.3.3.2.3. By End User
- 9.3.4. South Korea Cancer Gene Therapy Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.1.1. By Value
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Therapy
- 9.3.4.2.2. By Indication
- 9.3.4.2.3. By End User
- 9.3.5. Australia Cancer Gene Therapy Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.1.1. By Value
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Therapy
- 9.3.5.2.2. By Indication
- 9.3.5.2.3. By End User
- 10. South America Cancer Gene Therapy Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Therapy
- 10.2.2. By Indication
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Cancer Gene Therapy Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Therapy
- 10.3.1.2.2. By Indication
- 10.3.1.2.3. By End User
- 10.3.2. Argentina Cancer Gene Therapy Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Therapy
- 10.3.2.2.2. By Indication
- 10.3.2.2.3. By End User
- 10.3.3. Colombia Cancer Gene Therapy Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Therapy
- 10.3.3.2.2. By Indication
- 10.3.3.2.3. By End User
- 11. Middle East and Africa Cancer Gene Therapy Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Therapy
- 11.2.2. By Indication
- 11.2.3. By End User
- 11.2.4. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. South Africa Cancer Gene Therapy Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Therapy
- 11.3.1.2.2. By Indication
- 11.3.1.2.3. By End User
- 11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Therapy
- 11.3.2.2.2. By Indication
- 11.3.2.2.3. By End User
- 11.3.3. UAE Cancer Gene Therapy Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Therapy
- 11.3.3.2.2. By Indication
- 11.3.3.2.3. By End User
- 12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
- 13. Market Trends & Developments
- 13.1. Recent Developments
- 13.2. Mergers & Acquisitions
- 13.3. Product Launches
- 14. Competitive Landscape
- 14.1. Business Overview
- 14.2. Product Offerings
- 14.3. Recent Developments
- 14.4. Financials (As Reported)
- 14.5. Key Personnel
- 14.6. SWOT Analysis
- 14.6.1. Abeona Therapeutics Inc.
- 14.6.2. Asklepios BioPharmaceutical Inc.
- 14.6.3. Altor Bioscience Inc.
- 14.6.4. Bluebird bio-Inc.
- 14.6.5. BioCancell Inc.
- 14.6.6. Celgene Inc.
- 14.6.7. Elevate Bio Inc.
- 14.6.8. GlaxoSmithKline Inc.
- 14.6.9. Genelux Corporation
- 14.6.10. Introgen Therapeutics Inc.
- 14.6.11. OncoGenex Pharmaceuticals Inc.
- 14.6.12. Merck KGaA
- 15. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook